414
Views
13
CrossRef citations to date
0
Altmetric
Original Article

Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries

, , , , &
Pages 330-337 | Received 04 Mar 2016, Accepted 07 Jun 2016, Published online: 11 Jul 2016
 

Abstract

Objective: Although many studies have dealt with adverse effects (AEs) and quality of life (QoL) in prostate cancer (PCa) patients, the quantification of the patients’ perspective on AE-related reduction in QoL has been less studied. This study describes the impact of self-reported local (erectile, bowel, urinary dysfunction) or systemic (mental distress, fatigue, virility loss) AEs on QoL reduction.

Materials and methods: Nordic PCa patients completed a questionnaire containing 84 multiple-choice questions. The main outcome variable of the survey was patient-reported PCa-induced QoL reduction, assessed by descriptive and regression analyses. The level of significance was p < 0.05.

Results: Among 6200 patients, 39% described their QoL as reduced owing to the PCa trajectory: radical prostatectomy group (RPGroup): 42%, radiotherapy without hormones (RADGroup): 27%, hormones (HormGroup): 47% and no treatment (NoTrtGroup): 19%. Except for the NoTrtGroup, urinary leakage and fatigue doubled the risk of QoL reduction, while virility loss and erectile dysfunction tripled the risk. Significant intergroup differences emerged for the age-adjusted odds of QoL reduction: RPGroup (0.66), RADGroup (0.40), HormGroup (0.95) and NoTrtGroup (0.22).

Conclusions: After RP, RAD or hormone treatment of PCa, systemic AEs, in particular loss of virility, significantly reduce PCa patients’ QoL similarly to or more than local AEs. The probability of reduced QoL is highest during hormone treatment and lowest in patients without anticancer therapy, and seems lower in patients treated with RAD without hormones than after RP. The treatment-related risk of reduced QoL due to systemic AEs should become a part of the pretreatment counselling of patients.

Acknowledgements

We thank the Prostate Cancer Patients Advocate Organizations in Denmark (PROPA), Finland (PROPO), Norway (PROFO) and Sweden (PCF) for distributing the questionnaire to their members. We also thank the responders who volunteered to participate in the survey.

Disclosure statement

S.D. Fosså has occasionally served as an advisory consultant for Astellas in the Nordic countries and in the UK, as well as for Janssen in Norway. The authors have no other conflicts of interest.

Funding

The authors acknowledge the financial support by Astellas Nordic.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.